[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 21 of about 21
1. Fourni JW, Hawkins WE: Exocrine pancreatic carcinogenesis in the guppy Poecilia reticulata. Dis Aquat Organ; 2002 Dec 10;52(3):191-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pancreatic acinar cell adenomas and carcinomas occurred in 42 of 243 (17%) of the specimens exposed to MAM-Ac.
  • Acinar cell adenomas accounted for 27 of the 42 neoplasms.
  • Adenomas exhibited a high degree of acinar cell differentiation and some contained foci of atypical acinar cells that were less differentiated and more basophilic than were surrounding adenoma cells.
  • [MeSH-major] Adenoma / veterinary. Carcinoma, Acinar Cell / veterinary. Fish Diseases / chemically induced. Methylazoxymethanol Acetate / toxicity. Pancreatic Neoplasms / veterinary. Poecilia. Water Pollutants, Chemical / toxicity
  • [MeSH-minor] Animals. Dose-Response Relationship, Drug. Pancreas / pathology. Time Factors

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. METHYLAZOXYMETHANOL ACETATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12553447.001).
  • [ISSN] 0177-5103
  • [Journal-full-title] Diseases of aquatic organisms
  • [ISO-abbreviation] Dis. Aquat. Org.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Water Pollutants, Chemical; 592-62-1 / Methylazoxymethanol Acetate
  •  go-up   go-down


2. Yanase Y, Hiragun T, Kaneko S, Gould HJ, Greaves MW, Hide M: Detection of refractive index changes in individual living cells by means of surface plasmon resonance imaging. Biosens Bioelectron; 2010 Oct 15;26(2):674-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Real time imaging of living cell activation is an increasing demand in disciplines of life science and medicine.
  • We previously reported that surface plasmon resonance (SPR) sensors detect large changes of refractive index with living cells, such as mast cells, keratinocyte, human basophils and B-cells activated by biological stimuli.
  • The SPRI sensor could detect reactions of individual rat basophilic leukemia (RBL-2H3) cells, mouse keratinocyte (PAM212) cells, and human epidermal carcinoma (A431) cells in response to either specific or non-specific stimuli, such as antigen, phorbol ester or epidermal growth factor, with or without their inhibitors, resembling signals obtained by a conventional SPR sensor.
  • Moreover, we distinguished reactions of different type cells, co-cultured on a sensor chip, and revealed that the increase of refractive index around nuclei is rapid and potent as compared to that in peripheries in the reaction of RBL-2H3 cells against antigen.
  • [MeSH-major] Cell Physiological Phenomena. Refractometry / instrumentation. Signal Processing, Computer-Assisted / instrumentation. Surface Plasmon Resonance / instrumentation
  • [MeSH-minor] Animals. Cell Line. Equipment Design. Equipment Failure Analysis. Humans. Mice. Rats

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20673712.001).
  • [ISSN] 1873-4235
  • [Journal-full-title] Biosensors & bioelectronics
  • [ISO-abbreviation] Biosens Bioelectron
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0501494
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


3. Melgarejo E, Medina MA, Sánchez-Jiménez F, Urdiales JL: Targeting of histamine producing cells by EGCG: a green dart against inflammation? J Physiol Biochem; 2010 Sep;66(3):265-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The human body is made of some 250 different cell types.
  • From them, only a small subset of cell types is able to produce histamine.
  • In spite of the reduced number of these histamine-producing cell types, they are involved in very different physiological processes.
  • Their deregulation is related with many highly prevalent, as well as emergent and rare diseases, mainly those described as inflammation-dependent pathologies, including mastocytosis, basophilic leukemia, gastric ulcer, Crohn disease, and other inflammatory bowel diseases.
  • This is the case of melanoma, small cell lung carcinoma, and several types of neuroendocrine tumors.
  • [MeSH-major] Catechin / analogs & derivatives. Histamine / biosynthesis. Inflammation / drug therapy
  • [MeSH-minor] Anti-Inflammatory Agents / metabolism. Basophils / drug effects. Humans. Macrophages / drug effects. Megakaryocytes / drug effects. Monocytes / drug effects. Neurons / drug effects. Tea / chemistry

  • Hazardous Substances Data Bank. Green tea .
  • Hazardous Substances Data Bank. HISTAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cardiovasc Hematol Disord Drug Targets. 2007 Jun;7(2):135-44 [17584048.001]
  • [Cites] J Am Coll Nutr. 2006 Apr;25(2):79-99 [16582024.001]
  • [Cites] Monogr Allergy. 1978;13:1-113 [362171.001]
  • [Cites] J Immunol. 2004 Nov 1;173(9):5794-800 [15494532.001]
  • [Cites] Curr Opin Immunol. 1997 Dec;9(6):851-7 [9492989.001]
  • [Cites] Nutrition. 2002 May;18(5):443-4 [11985958.001]
  • [Cites] Arthritis Rheum. 2002 Aug;46(8):2079-86 [12209512.001]
  • [Cites] Cell Mol Life Sci. 2003 Aug;60(8):1760-3 [14521154.001]
  • [Cites] Cancer Causes Control. 1998 Mar;9(2):209-16 [9578298.001]
  • [Cites] J Nutr Biochem. 2010 Jul;21(7):659-64 [19616927.001]
  • [Cites] Neurosignals. 2005;14(1-2):46-60 [15956814.001]
  • [Cites] J Nutr. 1998 Dec;128(12):2334-40 [9868178.001]
  • [Cites] Cell Mol Life Sci. 2007 Oct;64(19-20):2690-701 [17878996.001]
  • [Cites] Nature. 1997 Jun 5;387(6633):561 [9177339.001]
  • [Cites] J Invest Dermatol. 2008 Oct;128(10 ):2429-41 [18463684.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Dec 7;364(1):79-85 [17927962.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Oct 4;297(4):700-13 [12359210.001]
  • [Cites] Prog Neurobiol. 2007 Aug;82(6):348-60 [17659826.001]
  • [Cites] PLoS One. 2007 Nov 07;2(11):e1153 [17987129.001]
  • [Cites] Biochem Biophys Res Commun. 2009 Feb 20;379(4):1033-7 [19150340.001]
  • [Cites] Mol Cancer Ther. 2005 Jan;4(1):81-90 [15657356.001]
  • [Cites] Arch Biochem Biophys. 2000 Apr 15;376(2):338-46 [10775421.001]
  • [Cites] Free Radic Biol Med. 2008 Mar 15;44(6):1032-41 [18206666.001]
  • [Cites] Free Radic Biol Med. 2006 Aug 15;41(4):549-56 [16863987.001]
  • [Cites] J Biomed Sci. 2003 Mar-Apr;10(2):219-27 [12595758.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Sep 22;348(2):524-31 [16889749.001]
  • [Cites] J Radiat Res. 2006 Jun;47(2):213-20 [16819147.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Apr 9;316(3):659-65 [15033450.001]
  • [Cites] Am J Med. 1999 May 31;106(5B):37S-42S [10390126.001]
  • [Cites] J Rheumatol. 2005 Oct;32(10):1958-67 [16206353.001]
  • [Cites] Arch Biochem Biophys. 2008 Aug 15;476(2):133-8 [18358230.001]
  • [Cites] Cancer Lett. 1995 Nov 27;98(1):27-31 [8529202.001]
  • [Cites] Prev Med. 1992 May;21(3):334-50 [1614995.001]
  • [Cites] J Oral Pathol Med. 2007 Nov;36(10):588-93 [17944751.001]
  • [Cites] Chem Pharm Bull (Tokyo). 1988 Jan;36(1):227-33 [3378286.001]
  • [Cites] Arch Biochem Biophys. 2003 Feb 1;410(1):177-85 [12559991.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Jan 11;365(2):310-5 [17996193.001]
  • [Cites] Br J Pharmacol. 2009 Dec;158(7):1705-12 [19912233.001]
  • [Cites] FASEB J. 2001 May;15(7):1309-11 [11344123.001]
  • [Cites] Crit Rev Biochem Mol Biol. 2003;38(1):23-59 [12641342.001]
  • [Cites] Mutat Res. 2003 Feb-Mar;523-524:119-25 [12628509.001]
  • [Cites] World J Gastroenterol. 2007 Feb 28;13(8):1162-9 [17451194.001]
  • [Cites] J Cell Biochem Suppl. 1997;27:68-75 [9591195.001]
  • [Cites] J Allergy Clin Immunol. 2005 Jan;115(1):186-91 [15637567.001]
  • [Cites] Arthritis Rheum. 2006 Aug;54(8):2393-401 [16869002.001]
  • [Cites] Mol Pharmacol. 2010 Jan;77(1):17-25 [19828731.001]
  • [Cites] J Agric Food Chem. 2001 May;49(5):2527-31 [11368631.001]
  • [Cites] J Agric Food Chem. 2002 Sep 25;50(20):5729-34 [12236706.001]
  • [Cites] Atherosclerosis. 2000 Jan;148(1):67-73 [10580172.001]
  • [Cites] J Agric Food Chem. 2003 Mar 26;51(7):1858-63 [12643642.001]
  • [Cites] Biochem Pharmacol. 2001 Nov 1;62(9):1175-83 [11705450.001]
  • [Cites] Chem Biol Interact. 2008 Jan 10;171(1):89-95 [17931610.001]
  • [Cites] J Agric Food Chem. 2007 Jan 24;55(2):299-304 [17227057.001]
  • [Cites] Int Immunopharmacol. 2002 May;2(6):849-55 [12095176.001]
  • [Cites] Mol Carcinog. 2006 May;45(5):309-19 [16508969.001]
  • [Cites] Nat Struct Mol Biol. 2004 Apr;11(4):380-1 [15024383.001]
  • [Cites] Mutat Res. 2003 Feb-Mar;523-524:201-8 [12628518.001]
  • [Cites] J Am Coll Nutr. 2002 Feb;21(1):1-13 [11838881.001]
  • [Cites] Ann N Y Acad Sci. 2002 Nov;973:435-7 [12485906.001]
  • [Cites] Free Radic Res Commun. 1987;2(4-6):289-94 [3504810.001]
  • [Cites] Nature. 1999 Apr 1;398(6726):381 [10201368.001]
  • [Cites] J Cell Biochem Suppl. 1997;27:59-67 [9591194.001]
  • [Cites] J Hypertens. 1999 Apr;17(4):457-63 [10404946.001]
  • [Cites] Biol Pharm Bull. 1995 Jul;18(7):1006-8 [7581239.001]
  • [Cites] Biochem Pharmacol. 1997 Dec 15;54(12):1281-6 [9393670.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Aug 11;274(3):603-8 [10924324.001]
  • [Cites] Am J Clin Nutr. 2005 Jan;81(1 Suppl):284S-291S [15640492.001]
  • (PMID = 20652470.001).
  • [ISSN] 1138-7548
  • [Journal-full-title] Journal of physiology and biochemistry
  • [ISO-abbreviation] J. Physiol. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Tea; 820484N8I3 / Histamine; 8R1V1STN48 / Catechin; BQM438CTEL / epigallocatechin gallate
  •  go-up   go-down


Advertisement
4. Ota Y, Imai T, Onose J, Takami S, Cho YM, Hirose M, Nishikawa A: A 55-week chronic toxicity study of dietary administered kojic acid (KA) in male F344 rats. J Toxicol Sci; 2009 Jun;34(3):305-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The major hematological findings were decreased red blood cell (RBC) count and hematocrit (Ht) values at both 0.5 and 2.0%.
  • Histopathologically, single cell necrosis of hepatocytes and proliferation of bile ductules in both treatment groups, and hypertrophy of hepatocytes, granulomas and proliferation of bile ducts in the 2.0% group were increased in incidence, and numbers and areas of glutathione-S-transferase placental-form (GST-P) positive foci were increased in the liver of the 2.0% group.
  • In the thyroids, diffuse follicular cell hyperplasia at 0.5 and 2.0% and focal follicular cell hyperplasia and follicular adenoma at 2.0% were increased.
  • A thyroid follicular carcinoma was also observed at 2.0%.
  • Additionally, increased incidences of hyaline casts and basophilic tubules in the kidneys at 2.0% and microgranulomas containing crystals in the lung in both treatment groups were noted.
  • [MeSH-major] Antioxidants / toxicity. Erythrocytes / drug effects. Food Additives / toxicity. Liver / drug effects. Pyrones / toxicity
  • [MeSH-minor] Administration, Oral. Animal Feed. Animals. Body Weight / drug effects. Cell Enlargement / drug effects. Eating / drug effects. Erythrocyte Count. Hematocrit. Hepatocytes / drug effects. Hepatocytes / pathology. Hypertrophy / chemically induced. Hypertrophy / pathology. Male. Necrosis / chemically induced. Necrosis / pathology. No-Observed-Adverse-Effect Level. Organ Size / drug effects. Precancerous Conditions / chemically induced. Precancerous Conditions / pathology. Rats. Rats, Inbred F344. Thyroid Gland / drug effects. Thyroid Gland / pathology. Toxicity Tests, Chronic. gamma-Glutamyltransferase / metabolism

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • Hazardous Substances Data Bank. KOJIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19483384.001).
  • [ISSN] 1880-3989
  • [Journal-full-title] The Journal of toxicological sciences
  • [ISO-abbreviation] J Toxicol Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Food Additives; 0 / Pyrones; 6K23F1TT52 / kojic acid; EC 2.3.2.2 / gamma-Glutamyltransferase
  •  go-up   go-down


5. National Toxicology Program: Toxicology and carcinogenesis studies of sodium dichromate dihydrate (Cas No. 7789-12-0) in F344/N rats and B6C3F1 mice (drinking water studies). Natl Toxicol Program Tech Rep Ser; 2008 Jul;(546):1-192
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidences of squamous cell carcinoma in the oral mucosa of 516 mg/L male and female rats were significantly greater than those in the controls.
  • The incidences of squamous cell papilloma or squamous cell carcinoma (combined) of the oral mucosa or tongue of 516 mg/L male and female rats were significantly greater than those in the controls.
  • Exposure concentration-related nonneoplastic liver lesions were observed in males and females exposed to 57.3 mg/L or greater.
  • These included histiocytic cellular infiltration, chronic inflammation, fatty change (females), basophilic focus (males), and clear cell focus (females).
  • Increased incidences of histiocytic cellular infiltration also occurred in the small intestine (duodenum), mesenteric lymph node, and pancreatic lymph node of males and/or females exposed to 57.3 mg/L or greater.
  • The incidence of carcinoma of the duodenum was significantly increased in 516 mg/L females.
  • When the incidences of adenoma and carcinoma were combined for all sites of the small intestine, the incidences were significantly increased in 85.7 and 257.4 mg/L males and 172 and 516 mg/L females compared to those in the controls.
  • CONCLUSIONS: Under the conditions of these 2-year drinking water studies, there was clear evidence of carcinogenic activity of sodium dichromate dihydrate in male and female F344/N rats based on increased incidences of squamous cell neoplasms of the oral cavity.
  • [MeSH-minor] Administration, Oral. Animals. Female. Intestinal Neoplasms / chemically induced. Intestinal Neoplasms / pathology. Intestine, Small / drug effects. Intestine, Small / pathology. Liver / drug effects. Liver / pathology. Lymph Nodes / drug effects. Lymph Nodes / pathology. Male. Mice. Mice, Inbred Strains. Mouth Neoplasms / chemically induced. Mouth Neoplasms / pathology. Rats. Rats, Inbred F344. Water Supply

  • Hazardous Substances Data Bank. SODIUM DICHROMATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18716633.001).
  • [ISSN] 0888-8051
  • [Journal-full-title] National Toxicology Program technical report series
  • [ISO-abbreviation] Natl Toxicol Program Tech Rep Ser
  • [Language] eng
  • [Publication-type] Journal Article; Technical Report
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromates; 0 / Water Pollutants, Chemical; C9G6VY6ZZ4 / sodium bichromate
  •  go-up   go-down


6. Zhang Y, Mi L, Xiong R, Wang PN, Chen JY, Yang W, Wang C, Peng Q: Subcellular Localization of Thiol-Capped CdTe Quantum Dots in Living Cells. Nanoscale Res Lett; 2009;4(7):606-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These unfunctionalized QDs were well internalized into human hepatocellular carcinoma and rat basophilic leukemia cells in vitro.
  • The movement of the endocytosed QDs toward the Golgi complex in the perinuclear region of the cell was demonstrated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20596411.001).
  • [ISSN] 1931-7573
  • [Journal-full-title] Nanoscale research letters
  • [ISO-abbreviation] Nanoscale Res Lett
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Meier F, Berner D, Scherwitz C, Rassner G, Metzler G: [An unusual case of pyoderma gangrenosum with necrotizing granulomatous dermatitis]. J Dtsch Dermatol Ges; 2003 Apr;1(4):302-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 64-year-old man presented with ulcerative pyoderma gangrenosum associated with renal cell carcinoma and IgA paraproteinemia; he responded to oral thalidomide.
  • Histopathology revealed unusual findings with signs of leukocytoclastic vasculitis, basophilic degeneration of collagen and zones of suppuration with a palisaded histiocytic and epithelioid granulomatous infiltration throughout the dermis.
  • [MeSH-major] Dermatitis / diagnosis. Dermatitis / drug therapy. Granuloma / diagnosis. Granuloma / drug therapy. Pyoderma Gangrenosum / diagnosis. Pyoderma Gangrenosum / drug therapy. Thalidomide / therapeutic use
  • [MeSH-minor] Humans. Male. Middle Aged. Rare Diseases / diagnosis. Rare Diseases / drug therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Pyoderma gangrenosum.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16285486.001).
  • [ISSN] 1610-0379
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


8. Kakehashi A, Kato A, Inoue M, Ishii N, Okazaki E, Wei M, Tachibana T, Wanibuchi H: Cytokeratin 8/18 as a new marker of mouse liver preneoplastic lesions. Toxicol Appl Pharmacol; 2010 Jan 1;242(1):47-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • To search for a reliable biomarker of preneoplastic lesions arising early in mouse hepatocarcinogenesis the proteomes of microdissected basophilic foci, hepatocellular adenomas (HCAs), carcinomas (HCCs) and normal-appearing liver of B6C3F1 mice initiated with diethylnitrosamine (DEN) were analysed on anionic (Q10) surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS) ProteinChip arrays.
  • Significant overexpression of cytokeratin 8 (CK8; m/z 54, 565), cytokeratin 18 (CK18; m/z 47,538) proteins was found in basophilic foci as well as in HCAs and HCCs.
  • Furthermore, immunohistochemistry demonstrated profound overexpression of CK8 and CK18 proteins (CK8/18) in all basophilic foci, mixed cell type foci, HCAs and HCCs in B6C3F1 and C57BL/6J mice initiated with DEN.
  • Moreover, formation of CK8 and CK18 complexes due to CK8 phosphorylation at Ser73 and Ser431 was found to be strongly associated with neoplastic transformation of mice liver basophilic foci.
  • Elevation of CK8/18 was strongly correlated with induction of cell proliferation in basophilic foci and tumors.
  • In conclusion, our data imply that CK8/18 is a novel reliable marker of preneoplastic lesions arising during mouse hepatocarcinogenesis which might be used for prediction of tumor development and evaluation of environmental agents as well as drugs and food additives using mouse liver tests.
  • [MeSH-major] Adenoma, Liver Cell / metabolism. Carcinoma, Hepatocellular / metabolism. Keratin-18 / metabolism. Keratin-8 / metabolism. Liver Neoplasms, Experimental / metabolism. Precancerous Conditions / metabolism
  • [MeSH-minor] Animals. Biomarkers, Tumor / analysis. Cell Proliferation. Immunohistochemistry. Male. Mice. Mice, Inbred C57BL. Microdissection. Paraffin Embedding. Protein Array Analysis. Risk Assessment. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19796649.001).
  • [ISSN] 1096-0333
  • [Journal-full-title] Toxicology and applied pharmacology
  • [ISO-abbreviation] Toxicol. Appl. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-18; 0 / Keratin-8
  •  go-up   go-down


9. Toxicology and carcinogenesis studies of androstenedione (CAS No. 63-05-8) in F344/N rats and B6C3F1 mice (gavage studies). Natl Toxicol Program Tech Rep Ser; 2010 Sep;(560):1, 7-31,33-171 passim
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidences of mononuclear cell leukemia were significantly increased in 20 and 50 mg/kg females and significantly decreased in 20 and 50 mg/kg males.
  • Incidences of alveolar/bronchiolar adenoma and alveolar/bronchiolar adenoma or carcinoma (combined) were significantly increased in 20 mg/kg males.
  • The incidence of testicular interstitial cell adenoma (including bilateral) was significantly decreased in 50 mg/kg males.
  • In the liver of males, the incidences of basophilic focus in all dosed groups, the incidence of clear cell focus in the 20 mg/kg group, and the incidence of eosinophilic focus in the 50 mg/kg group were significantly increased.
  • In females, the incidences of hepatocellular carcinoma were significantly increased in all dosed groups.
  • Incidences of hepatocellular adenoma or carcinoma (combined) in males and females were significantly increased in the 50 mg/kg groups.
  • The incidence of eosinophilic focus was significantly increased in 50 mg/kg males, and the incidences of mixed cell focus and cytoplasmic vacuolization were significantly increased in 50 mg/kg females.
  • CONCLUSIONS: under the conditions of these 2-year gavage studies, there was equivocal evidence of carcinogenic activity of androstenedione in male F344/N rats based on increased incidences of alveolar/bronchiolar adenoma and alveolar/bronchiolar adenoma or carcinoma (combined).
  • There was equivocal evidence of carcinogenic activity of androstenedione in female F344/N rats based on increased incidences of mononuclear cell leukemia.
  • There was clear evidence of carcinogenic activity of androstenedione in male B6C3F1 mice based on increased incidences of multiple hepatocellular adenoma and hepatocellular carcinoma and increased incidence of hepatoblastoma.
  • There was clear evidence of carcinogenic activity of androstenedione in female B6C3F1 mice based on increased incidences of hepatocellular adenoma and hepatocellular carcinoma.
  • Decreases in the incidences of testicular interstitial cell adenoma in male rats, mammary gland fibroadenoma, cysts, and hyperplasia in female rats, and malignant lymphoma in female mice were considered related to androstenedione administration.
  • [MeSH-minor] Animal Feed. Animals. Biomarkers. Body Weight / drug effects. Carcinogenicity Tests. Chemistry, Pharmaceutical. Dose-Response Relationship, Drug. Drug-Induced Liver Injury / metabolism. Drug-Induced Liver Injury / pathology. Estrous Cycle. Female. Genitalia / drug effects. Intubation, Gastrointestinal. Male. Mice. Mice, Inbred Strains. Micronucleus Tests. Mutagens / toxicity. Organ Size / drug effects. Rats. Rats, Inbred F344

  • Hazardous Substances Data Bank. ANDROSTENEDIONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21037592.001).
  • [ISSN] 0888-8051
  • [Journal-full-title] National Toxicology Program technical report series
  • [ISO-abbreviation] Natl Toxicol Program Tech Rep Ser
  • [Language] eng
  • [Publication-type] Journal Article; Review; Technical Report
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Mutagens; 409J2J96VR / Androstenedione
  •  go-up   go-down


10. Madden CR, Finegold MJ, Slagle BL: Hepatitis B virus X protein acts as a tumor promoter in development of diethylnitrosamine-induced preneoplastic lesions. J Virol; 2001 Apr;75(8):3851-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chronic infection with hepatitis B virus (HBV) is one of the major etiological factors in the development of human hepatocellular carcinoma.
  • Although the mechanism for this cofactor role remains unknown, the ability of HBx to inhibit DNA repair and to influence cell cycle progression suggests two possible pathways.
  • Histological examination of liver tissue confirmed that DEN-treated ATX mice developed approximately twice as many focal lesions of basophilic hepatocytes as treated wild-type littermates.
  • Importantly, the extent of hepatocellular proliferation in 14-day-old mice, as measured by the detection of proliferating cell nuclear antigen and by the incorporation of 5-bromo-2'-deoxyuridine, was determined to be approximately twofold higher in ATX livers than in wild-type livers.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. N-NITROSODIETHYLAMINE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Histochem Cytochem. 2000 Mar;48(3):355-62 [10681389.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9073-8 [8799156.001]
  • [Cites] Environ Mol Mutagen. 2000;35(4):319-27 [10861950.001]
  • [Cites] Cancer Res. 1983 Mar;43(3):1261-8 [6825098.001]
  • [Cites] Carcinogenesis. 1985 Apr;6(4):625-9 [3986964.001]
  • [Cites] Cancer. 1988 May 15;61(10):1942-56 [2834034.001]
  • [Cites] Hepatology. 1989 Feb;9(2):322-7 [2643549.001]
  • [Cites] Carcinogenesis. 1990 Jun;11(6):953-6 [2347070.001]
  • [Cites] Mutat Res. 1990 Jul;231(1):11-30 [2195323.001]
  • [Cites] J Virol. 1990 Dec;64(12):5939-47 [2243380.001]
  • [Cites] Cancer Res. 1991 Oct 1;51(19):5188-97 [1655249.001]
  • [Cites] J Med Virol. 1992 Feb;36(2):101-17 [1583465.001]
  • [Cites] Prog Med Virol. 1992;39:167-203 [1317597.001]
  • [Cites] Adv Cancer Res. 1992;59:167-226 [1325733.001]
  • [Cites] J Virol. 1992 Nov;66(11):6819-23 [1357192.001]
  • [Cites] J Virol. 1993 Mar;67(3):1218-26 [8437213.001]
  • [Cites] Nature. 1993 Feb 25;361(6414):742-5 [8441471.001]
  • [Cites] Oncogene. 1993 May;8(5):1109-17 [8386823.001]
  • [Cites] J Virol. 1994 Mar;68(3):2026-30 [8107266.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Mar 15;91(6):2230-4 [8134379.001]
  • [Cites] J Clin Invest. 1994 Jul;94(1):44-9 [8040286.001]
  • [Cites] Oncogene. 1994 Oct;9(10):2837-43 [8084589.001]
  • [Cites] Mol Carcinog. 1994 Oct;11(2):74-80 [7916995.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Oct 25;91(22):10350-4 [7937954.001]
  • [Cites] J Virol. 1995 Feb;69(2):1107-14 [7815490.001]
  • [Cites] J Hepatol. 1995;22(1 Suppl):34-7 [7602073.001]
  • [Cites] J Virol. 1995 Sep;69(9):5912-6 [7637040.001]
  • [Cites] Annu Rev Biochem. 1996;65:135-67 [8811177.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):10578-83 [8855220.001]
  • [Cites] Oncogene. 1997 Jan 30;14(4):395-404 [9053836.001]
  • [Cites] Oncogene. 1997 Feb 13;14(6):629-40 [9038370.001]
  • [Cites] J Hepatol. 1997 Jan;26(1):119-30 [9148002.001]
  • [Cites] Am J Pathol. 1997 Apr;150(4):1141-57 [9094970.001]
  • [Cites] J Virol. 1997 Aug;71(8):6194-9 [9223516.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Aug 5;94(16):8744-9 [9238048.001]
  • [Cites] Mol Cell Biol. 1997 Nov;17(11):6427-36 [9343405.001]
  • [Cites] J Gastroenterol Hepatol. 1997 Oct;12(9-10):S294-308 [9407350.001]
  • [Cites] J Biol Chem. 1998 Jan 2;273(1):381-5 [9417092.001]
  • [Cites] J Virol. 1998 Jan;72(1):266-72 [9420223.001]
  • [Cites] Hepatology. 1998 Feb;27(2):383-91 [9462635.001]
  • [Cites] Mutagenesis. 1998 Mar;13(2):173-9 [9568591.001]
  • [Cites] Hepatology. 1998 Sep;28(3):717-26 [9731564.001]
  • [Cites] Am J Pathol. 1998 Sep;153(3):955-61 [9736044.001]
  • [Cites] J Biol Chem. 1998 Sep 25;273(39):25510-5 [9738022.001]
  • [Cites] J Biol Chem. 1998 Dec 11;273(50):33327-32 [9837906.001]
  • [Cites] Biomed Pharmacother. 1998;52(9):363-8 [9856282.001]
  • [Cites] Toxicol Lett. 1998 Dec 28;102-103:595-601 [10022319.001]
  • [Cites] Cancer Lett. 1998 Dec 25;134(2):181-6 [10025879.001]
  • [Cites] Int J Cancer. 1999 Mar 15;80(6):875-9 [10074921.001]
  • [Cites] Biochim Biophys Acta. 1999 Mar 30;1453(3):330-40 [10101251.001]
  • [Cites] Carcinogenesis. 1999 Mar;20(3):479-83 [10190565.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):33-64, 1 [10200776.001]
  • [Cites] Hepatology. 1999 Aug;30(2):379-83 [10421643.001]
  • [Cites] Br J Cancer. 1999 Jul;80 Suppl 1:34-7 [10466759.001]
  • [Cites] J Virol. 1995 Oct;69(10):6158-69 [7666518.001]
  • [Cites] EMBO J. 1995 Oct 2;14(19):4747-57 [7588604.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):11215-9 [7479968.001]
  • [Cites] Mol Carcinog. 1996 Apr;15(4):261-9 [8634084.001]
  • [Cites] J Virol. 1996 Aug;70(8):5246-54 [8764034.001]
  • [Cites] J Virol. 2000 Jun;74(11):5266-72 [10799603.001]
  • (PMID = 11264374.001).
  • [ISSN] 0022-538X
  • [Journal-full-title] Journal of virology
  • [ISO-abbreviation] J. Virol.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / T32 DK007664; United States / NCI NIH HHS / CA / CA54557; United States / NIDDK NIH HHS / DK / T32DK07664
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proliferating Cell Nuclear Antigen; 0 / Trans-Activators; 0 / hepatitis B virus X protein; 3IQ78TTX1A / Diethylnitrosamine; 9007-49-2 / DNA
  • [Other-IDs] NLM/ PMC114876
  •  go-up   go-down


11. Markopoulos A, Albanidou-Farmaki E, Kayavis I: Actinic cheilitis: clinical and pathologic characteristics in 65 cases. Oral Dis; 2004 Jul;10(4):212-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY DESIGN: A retrospective study on 65 patients attending an Oral Medicine clinic in Greece over a 10 year period.
  • The histopathologic characteristics included increased thickness of keratin layer, alterations of the thickness of spinous cell layer, epithelial dysplasia, connective tissue changes, perivascular inflammation and basophilic changes of connective tissue.
  • In 11 cases (16.9%) the presence of squamous cell carcinoma was observed.
  • CONCLUSIONS: This case-series highlights varied clinical presentation of actinic cheilitis among whom a high proportion developed squamous cell carcinoma.
  • [MeSH-minor] Carcinoma, Squamous Cell / etiology. Cell Transformation, Neoplastic. Female. Greece. Humans. Lip Neoplasms / etiology. Male. Middle Aged. Occupational Diseases / complications. Occupational Diseases / pathology. Retrospective Studies. Smoking / adverse effects

  • Genetic Alliance. consumer health - Actinic Cheilitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15196142.001).
  • [ISSN] 1354-523X
  • [Journal-full-title] Oral diseases
  • [ISO-abbreviation] Oral Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


12. Bannasch P: Hormonal and hormone-like effects eliciting hepatocarcinogenesis. Folia Histochem Cytobiol; 2001;39 Suppl 2:28-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 1) the glycogenotic-basophilic cell lineage, 2) its xenomorphic-tigroid cell variant, and 3) the amphophilic-basophilic cell lineage.
  • The predominant glycogenotic-basophilic and tigroid cell lineages developed especially after exposure to DNA-reactive chemicals, radiation, viruses, transgenic oncogenes and local hyperinsulinism.
  • The early phenotypes of these lineages indicate an initiation by insulin or insulinomimetic effects of the oncogenic agents, triggering the raf-Map kinase signal transduction pathway.
  • In contrast, the amphophilic-basophilic cell lineage has mainly been observed after exposure of rodents to not directly DNA-reactive peroxisome proliferators but also hepadnaviridae, its biochemical pattern mimiking an effect of thyroid hormone.


13. George MH, Olson GR, Doerfler D, Moore T, Kilburn S, DeAngelo AB: Carcinogenicity of bromodichloromethane administered in drinking water to Male F344/N Rats and B6C3F1 mice. Int J Toxicol; 2002 May-Jun;21(3):219-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The prevalence of basophilic and clear cell, but not eosinophilic cells, altered foci of cells declined with increasing dose.
  • [MeSH-major] Carcinogens / toxicity. Carcinoma / chemically induced. Liver Neoplasms, Experimental / chemically induced. Trihalomethanes / toxicity
  • [MeSH-minor] Animals. Dose-Response Relationship, Drug. Drinking / drug effects. Male. Mice. Mice, Inbred Strains. Organ Specificity. Rats. Rats, Inbred F344. Species Specificity. Water Supply / standards

  • Hazardous Substances Data Bank. BROMODICHLOROMETHANE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12055023.001).
  • [ISSN] 1091-5818
  • [Journal-full-title] International journal of toxicology
  • [ISO-abbreviation] Int. J. Toxicol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Trihalomethanes; 7LN464CH2O / bromodichloromethane
  •  go-up   go-down


14. Hard GC: Significance of the renal effects of ethyl benzene in rodents for assessing human carcinogenic risk. Toxicol Sci; 2002 Sep;69(1):30-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The vast majority of the proliferative lesions were of basophilic type and, apart from three carcinomas in the high-dose males, either small adenomas or foci of ATH.
  • Almost all of the basophilic tumors occurred in rats with advanced, usually end-stage, CPN, and they were located in areas of parenchyma involved in the CPN disease process.
  • Careful examination of renal tubules revealed no evidence of renal tubule injury or increased mitotic activity that would support sustained cytotoxicity/cell regeneration as a mode of action for tumor development.
  • [MeSH-minor] Adenoma / chemically induced. Adenoma / pathology. Animals. Carcinoma / chemically induced. Carcinoma / pathology. Chronic Disease. Disease Progression. Female. Humans. Hyperplasia / pathology. Kidney / pathology. Kidney Neoplasms / chemically induced. Kidney Neoplasms / pathology. Kidney Tubules / pathology. Male. Rats. Regeneration / drug effects. Risk Assessment

  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • Hazardous Substances Data Bank. ETHYLBENZENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12215658.001).
  • [ISSN] 1096-6080
  • [Journal-full-title] Toxicological sciences : an official journal of the Society of Toxicology
  • [ISO-abbreviation] Toxicol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzene Derivatives; 0 / Carcinogens; L5I45M5G0O / ethylbenzene
  •  go-up   go-down


15. Viardot-Helmer A, Ott H, Sauer I, Merk HF: [Basophil activation test as in vitro assay for cisplatin allergy]. Hautarzt; 2008 Nov;59(11):883-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Basophil activation test as in vitro assay for cisplatin allergy].
  • During chemoembolization with gemcitabine, mitomycin and cisplatin of a cholangiocellular carcinoma and after receiving iodide contrast media, a 49-year-old patient developed a grade III anaphylactic reaction.
  • Using the basophil activation test, we demonstrated a hypersensitivity reaction to cisplatin with distinct induction of CD63-expression on basophilic granulocytes.
  • [MeSH-major] Anaphylaxis / chemically induced. Anaphylaxis / diagnosis. Antigens, CD / immunology. Basophil Degranulation Test / methods. Cisplatin / adverse effects. Drug Eruptions / diagnosis. Drug Eruptions / etiology. Platelet Membrane Glycoproteins / immunology
  • [MeSH-minor] Antigens, CD63. Antineoplastic Agents / adverse effects. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Anaphylaxis.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int Arch Allergy Immunol. 2005 Mar;136(3):230-8 [15713985.001]
  • [Cites] Zentralbl Gynakol. 1996;118(12):684-8 [9082708.001]
  • [Cites] J Allergy Clin Immunol. 2008 Sep;122(3):574-80 [18502492.001]
  • [Cites] Cancer Chemother Pharmacol. 1995;35(4):349-51 [7828281.001]
  • [Cites] Cytometry B Clin Cytom. 2008 Jul;74(4):201-10 [18412216.001]
  • [Cites] Int Arch Allergy Immunol. 2008;145(1):54-7 [17703101.001]
  • [Cites] Hautarzt. 2006 Jun;57(6):502, 504-8 [16752146.001]
  • [Cites] Hautarzt. 2005 Jan;56(1):38-43 [15625602.001]
  • [Cites] J Allergy Clin Immunol. 2007 Mar;119(3):726-30 [17258305.001]
  • (PMID = 18931982.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD63; 0 / Antineoplastic Agents; 0 / CD63 protein, human; 0 / Platelet Membrane Glycoproteins; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


16. Thors L, Alajakku K, Fowler CJ: The 'specific' tyrosine kinase inhibitor genistein inhibits the enzymic hydrolysis of anandamide: implications for anandamide uptake. Br J Pharmacol; 2007 Apr;150(7):951-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND PURPOSE: The cellular uptake of anandamide is reduced by inhibitors of fatty acid amide hydrolase (FAAH) and by agents disrupting endocytotic mechanisms.
  • We have therefore investigated the effects of such compounds in three cell lines of different origins using different assay incubation times and temperatures.
  • KEY RESULTS: The FAAH inhibitor URB597 inhibited the uptake of anandamide into C6 glioma, RBL2H3 basophilic leukaemia cells and P19 embryonic carcinoma cells at incubation time 4 min.
  • The FAAH- resistant but time-dependent uptake of anandamide is seen in all three cell lines studied and is thus presumably a generally occurring process.
  • [MeSH-major] Amidohydrolases / antagonists & inhibitors. Arachidonic Acids / metabolism. Genistein / pharmacology. Polyunsaturated Alkamides / metabolism
  • [MeSH-minor] Animals. Benzamides / pharmacology. Brain / enzymology. Carbamates / pharmacology. Cell Line, Tumor. Endocannabinoids. Hydrolysis. Mice. Nystatin / pharmacology. Progesterone / pharmacology. Protein Kinase Inhibitors / pharmacology. Protein-Tyrosine Kinases / antagonists & inhibitors. Rats

  • Hazardous Substances Data Bank. NYSTATIN .
  • Hazardous Substances Data Bank. GENISTEIN .
  • Hazardous Substances Data Bank. PROGESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2004 Oct 1;279(40):41991-7 [15292270.001]
  • [Cites] Fundam Clin Pharmacol. 2006 Dec;20(6):549-62 [17109648.001]
  • [Cites] J Biol Chem. 1985 Nov 15;260(26):14145-9 [4055775.001]
  • [Cites] J Biol Chem. 1987 Apr 25;262(12):5592-5 [3106339.001]
  • [Cites] Science. 1992 Dec 18;258(5090):1946-9 [1470919.001]
  • [Cites] Biochem Pharmacol. 1993 Sep 1;46(5):791-6 [8373432.001]
  • [Cites] Nature. 1994 Dec 15;372(6507):686-91 [7990962.001]
  • [Cites] J Biol Chem. 1997 Feb 7;272(6):3315-23 [9013571.001]
  • [Cites] J Neurochem. 1997 Aug;69(2):631-8 [9231721.001]
  • [Cites] J Biol Chem. 1997 Aug 22;272(34):21181-6 [9261124.001]
  • [Cites] Science. 1997 Aug 22;277(5329):1094-7 [9262477.001]
  • [Cites] Life Sci. 1998;62(14):1223-9 [9570337.001]
  • [Cites] Glia. 1999 Jul;27(1):22-31 [10401629.001]
  • [Cites] Nature. 1999 Jul 29;400(6743):452-7 [10440374.001]
  • [Cites] Br J Pharmacol. 2004 Nov;143(6):774-84 [15492019.001]
  • [Cites] Cell Mol Life Sci. 2005 Feb;62(3):386-95 [15723173.001]
  • [Cites] Chem Phys Lipids. 2005 Apr;134(2):131-9 [15784231.001]
  • [Cites] J Pharmacol Exp Ther. 2000 Mar;292(3):960-7 [10688610.001]
  • [Cites] J Biol Chem. 2000 Jun 9;275(23):17221-4 [10770957.001]
  • [Cites] Chem Phys Lipids. 2000 Nov;108(1-2):123-34 [11106786.001]
  • [Cites] Vitam Horm. 2001;62:95-131 [11345902.001]
  • [Cites] Mol Pharmacol. 2001 Jun;59(6):1369-75 [11353795.001]
  • [Cites] J Biol Chem. 2001 Mar 9;276(10):6967-73 [11118429.001]
  • [Cites] Br J Pharmacol. 2001 Oct;134(4):845-52 [11606325.001]
  • [Cites] J Pharmacol Exp Ther. 2002 Jun;301(3):900-7 [12023517.001]
  • [Cites] Prostaglandins Leukot Essent Fatty Acids. 2002 Feb-Mar;66(2-3):211-20 [12052037.001]
  • [Cites] Br J Anaesth. 2002 Dec;89(6):882-7 [12453933.001]
  • [Cites] Nat Med. 2003 Jan;9(1):76-81 [12461523.001]
  • [Cites] J Cell Sci. 2003 Mar 15;116(Pt 6):1059-71 [12584249.001]
  • [Cites] J Biol Chem. 2005 Apr 1;280(13):12212-20 [15657045.001]
  • [Cites] Neuropharmacology. 2005 Jun;48(8):1072-8 [15910883.001]
  • [Cites] J Lipid Res. 2005 Aug;46(8):1652-9 [15930521.001]
  • [Cites] Br J Pharmacol. 2005 Oct;146(3):467-76 [16100529.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4269-74 [12655057.001]
  • [Cites] Br J Pharmacol. 2003 Jul;139(5):1005-13 [12839875.001]
  • [Cites] J Lipid Res. 2003 Sep;44(9):1790-4 [12837852.001]
  • [Cites] Br J Pharmacol. 2003 Nov;140(5):802-8 [12970089.001]
  • [Cites] Br J Pharmacol. 2004 Feb;141(3):457-67 [14718261.001]
  • [Cites] J Neurosci. 2004 Feb 18;24(7):1673-9 [14973237.001]
  • [Cites] J Pharmacol Exp Ther. 2004 May;309(2):745-57 [14757851.001]
  • [Cites] Biochem J. 2004 May 15;380(Pt 1):265-72 [14969584.001]
  • [Cites] Eur J Pharmacol. 2004 May 10;492(1):1-11 [15145699.001]
  • [Cites] Eur J Pharm Sci. 2004 Jun;22(2-3):181-9 [15158903.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 8;101(23):8756-61 [15138300.001]
  • [Cites] Biochemistry. 2004 Jun 29;43(25):8184-90 [15209515.001]
  • [Cites] J Biochem Biophys Methods. 2004 Aug 31;60(2):171-7 [15262451.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18620-5 [16352709.001]
  • [Cites] Br J Pharmacol. 2006 Feb;147(3):281-8 [16331291.001]
  • [Cites] J Med Chem. 2006 Apr 6;49(7):2320-32 [16570928.001]
  • [Cites] J Biol Chem. 2006 Apr 7;281(14):9066-75 [16461355.001]
  • [Cites] Br J Pharmacol. 2006 Sep;149(1):73-81 [16865094.001]
  • [Cites] Pharmacol Res. 2006 Nov;54(5):341-4 [16935521.001]
  • [Cites] Pharmacol Res. 2006 Dec;54(6):481-5 [16997568.001]
  • [Cites] Biochem J. 1974 Jun;139(3):715-20 [4854723.001]
  • (PMID = 17325653.001).
  • [ISSN] 0007-1188
  • [Journal-full-title] British journal of pharmacology
  • [ISO-abbreviation] Br. J. Pharmacol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Arachidonic Acids; 0 / Benzamides; 0 / Carbamates; 0 / Endocannabinoids; 0 / Polyunsaturated Alkamides; 0 / Protein Kinase Inhibitors; 0 / cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester; 1400-61-9 / Nystatin; 4G7DS2Q64Y / Progesterone; 94421-68-8 / anandamide; DH2M523P0H / Genistein; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 3.5.- / Amidohydrolases; EC 3.5.1.- / fatty-acid amide hydrolase
  • [Other-IDs] NLM/ PMC2013877
  •  go-up   go-down


17. National Toxicology Program, Public Health Service, National Institutes of Health, US Department of Health and Human Services: Toxicology and carcinogenesis studies of o-nitrotoluene sulfone (CAS no. 88-72-2) in F344/N rats and B6C3F(1) mice (feed studies). Natl Toxicol Program Tech Rep Ser; 2002 May;(504):1-357
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The incidences of hepatocellular adenoma in 2,000 ppm core study males and females and of hepatocellular adenoma or carcinoma (combined) in 2,000 ppm core study and 5,000 ppm stop-exposure males were significantly increased.
  • Nonneoplastic lesions of the liver included eosinophilic, mixed cell, and clear cell foci in exposed groups of males and females and mixed cell infiltrate in exposed males and basophilic focus in exposed females.
  • The incidences of alveolar/bronchiolar adenoma and alveolar/bronchiolar adenoma or carcinoma (combined) were significantly increased in 5,000 ppm stop-exposure males, as were alveolar/bronchiolar hyperplasia in most exposed groups of males and females.
  • The incidences of hematopoietic cell proliferation of the spleen and of hyperplasia of the mandibular lymph node (females) and bone marrow were increased in exposed groups of males at 3 months and/or 2 years and in exposed groups of females at 2 years.
  • The incidences of mononuclear cell leukemia were significantly decreased in all groups of males exposed to 1,250 ppm or greater and in all exposed groups of females; the incidence of testicular interstitial cell adenoma was significantly decreased in 5,000 ppm stop-exposure males.
  • Nonneoplastic liver lesions including eosinophilic and basophilic foci and minimal to mild necrosis were enhanced in exposed males and females.
  • There was clear evidence of carcinogenic activity of -o-nitrotoluene in male and female mice based on increased incidences of hemangiosarcoma, carcinoma of the large intestine (cecum), and hepatocellular neoplasms (females only).
  • Decreased incidences of mononuclear cell leukemia occurred in exposed groups of rats; the incidence of testicular interstitial cell adenoma was decreased in exposed male rats.
  • [MeSH-minor] Administration, Oral. Animals. CHO Cells. Carcinogenicity Tests. Cricetinae. Diet. Dose-Response Relationship, Drug. Female. In Vitro Techniques. Injections, Intraperitoneal. Longevity / drug effects. Male. Mice. Mice, Inbred Strains. Mutagenicity Tests. Rats. Rats, Inbred F344

  • Hazardous Substances Data Bank. TOLUENE .
  • Hazardous Substances Data Bank. 2-NITROTOLUENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12087420.001).
  • [ISSN] 0888-8051
  • [Journal-full-title] National Toxicology Program technical report series
  • [ISO-abbreviation] Natl Toxicol Program Tech Rep Ser
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Mutagens; 3FPU23BG52 / Toluene; 6Q9N88YIAY / 2-nitrotoluene
  •  go-up   go-down


18. Evert M, Schneider-Stock R, Dombrowski F: Overexpression of fatty acid synthase in chemically and hormonally induced hepatocarcinogenesis of the rat. Lab Invest; 2005 Jan;85(1):99-108
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fatty acid synthase (FAS) is the key enzyme of de novo fatty acid synthesis and has been shown to be involved in carcinogenesis of numerous human malignancies, including breast, colorectal, and prostate carcinomas, often associated with a worse prognosis.
  • Preneoplastic clear-cell foci of altered hepatocytes (FAH), harvested after laser-microdissection of kryostat sections, showed an overexpression of FAS messenger RNA in gene expression profiles, done by array-hybridization, and in quantitative RT-PCR (Light-Cycler).
  • In the NNM-model, FAS protein was also overexpressed in the vast majority (87%) of glycogenotic FAH and neoplasms, in particular in the diabetic animals.
  • Also two spontaneous glycogenotic FAH in control animals displayed strong FAS overexpression.
  • Basophilic lesions and neoplasms, which occasionally develop out of the primary clear-cell FAH at later stages of carcinogenesis, however, lost FAS overexpression.
  • In conclusion, FAS overexpression is an early phenonemon in spontaneous, hormonally and chemically induced rat hepatocarcinogenesis, demonstrable in early clear-cell (glycogenotic) FAH and hepatocellular neoplasms.
  • [MeSH-major] Adenoma / enzymology. Carcinoma / enzymology. Diabetes Mellitus, Experimental / enzymology. Fatty Acid Synthases / metabolism. Liver Neoplasms, Experimental / enzymology
  • [MeSH-minor] Animals. Disease Models, Animal. Fluorescent Antibody Technique, Indirect. Gene Expression Profiling. Hepatocytes / drug effects. Hepatocytes / enzymology. Hepatocytes / pathology. Islets of Langerhans Transplantation / pathology. Liver / pathology. Male. Precancerous Conditions / chemically induced. Precancerous Conditions / enzymology. Precancerous Conditions / pathology. RNA, Messenger / metabolism. Rats. Rats, Inbred Lew. Reverse Transcriptase Polymerase Chain Reaction

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15543204.001).
  • [ISSN] 0023-6837
  • [Journal-full-title] Laboratory investigation; a journal of technical methods and pathology
  • [ISO-abbreviation] Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.3.1.85 / Fatty Acid Synthases
  •  go-up   go-down


19. Hard GC, Seely JC, Betz LJ, Hayashi SM: Re-evaluation of the kidney tumors and renal histopathology occurring in a 2-year rat carcinogenicity bioassay of quercetin. Food Chem Toxicol; 2007 Apr;45(4):600-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The re-evaluation confirmed the reported increase in renal tumors in mid- and high-dose males, including a single carcinoma in a high-dose male, as well as an exacerbation of spontaneous, chronic progressive nephropathy (CPN) in male rats only.
  • The evidence linked the occurrence of the predominant basophilic adenomas and foci of atypical tubule hyperplasia (ATH) with the exacerbation of CPN to advanced grades of severity, supporting a mode of action involving quercetin interaction with CPN.
  • In addition, the single carcinoma present in the high-dose males, along with 4 other lesions ranging from ATH to adenoma in male and female groups, were considered to have a unique phenotype associated previously with neoplasms of spontaneous and familial origin.
  • [MeSH-major] Carcinogenicity Tests. Kidney / drug effects. Kidney Neoplasms / chemically induced. Quercetin / toxicity
  • [MeSH-minor] Animals. Female. Hyperplasia. Kidney Tubules / drug effects. Kidney Tubules / pathology. Male. Rats. Rats, Inbred F344

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. QUERCETIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17156907.001).
  • [ISSN] 0278-6915
  • [Journal-full-title] Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  • [ISO-abbreviation] Food Chem. Toxicol.
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / 1-ES-95435
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 9IKM0I5T1E / Quercetin
  •  go-up   go-down


20. Mukherjee B, Das T, Ghosh S, Datta S: Changes in the antioxidant defense and hepatic drug metabolizing enzyme and isoenzyme levels, 8-hydroxydeoxyguanosine formation and expressions of c-raf.1 and insulin-like growth factor II genes during the stages of development of hepatocellular carcinoma in rats. Eur J Cancer Prev; 2007 Aug;16(4):363-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Changes in the antioxidant defense and hepatic drug metabolizing enzyme and isoenzyme levels, 8-hydroxydeoxyguanosine formation and expressions of c-raf.1 and insulin-like growth factor II genes during the stages of development of hepatocellular carcinoma in rats.
  • This is an extensive study in a defined initiation-promotion hepatocellular carcinoma model of hepatocarcinogenesis (in rats) in which many important marker enzymes and isoenzymes and 8-hydroxydeoxyguanosine formation have been studied together with two very important cellular proliferating genes, insulin-like growth factor II and c-raf.1, known for their role in hepatocellular cancer development.
  • In this study, glutathione peroxidase (1.14 and 1.46-fold) and reduced triphosphopyridine nucleotide (TPNH)-cytochrome-c-reductase (1.94 and 2.94-fold) activities, cytochrome b5 (1.57 and 3.28-fold) and P-450 contents (1.45 and 1.22-fold), glutathione content (1.27 and 1.45-fold) and superoxide dismutase and catalase (1.16 and 1.39-fold) activities in group A animals were found to be lower than those in initiation and promotion studies, respectively.
  • The insulin-like growth factor II expression was found to be predominant in hepatocellular carcinoma and in early preneoplastic lesions.
  • Unlike insulin-like growth factor II, c-raf.1 expression was located in the late basophilic lesions associated with hepatocellular carcinoma.
  • During the various stages of the development of hepatocellular carcinoma, the enzymes played a significant role in metabolizing carcinogens and thereby scavenging various toxic metabolites or free radicals produced.
  • A sequence of cellular changes starting from the appearance of glycogen storage foci to basophilic foci leading to hepatocellular carcinoma via mixed cell foci varied the activity/content or expression pattern of the enzymes and isoenzymes and in 8-hydroxydeoxyguanosine formation.
  • [MeSH-major] Antioxidants / metabolism. Carcinoma, Hepatocellular / pathology. Deoxyguanosine / analogs & derivatives. Inactivation, Metabolic. Insulin-Like Growth Factor II / genetics. Liver / enzymology. Proto-Oncogene Proteins c-raf / genetics
  • [MeSH-minor] Animals. Cell Nucleus / metabolism. Gene Expression Regulation, Neoplastic. Glucose-6-Phosphatase / metabolism. Glutathione / metabolism. Isoenzymes / metabolism. Male. Precancerous Conditions / enzymology. Precancerous Conditions / genetics. Precancerous Conditions / pathology. Rats. Rats, Sprague-Dawley

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17554210.001).
  • [ISSN] 0959-8278
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Isoenzymes; 67763-97-7 / Insulin-Like Growth Factor II; 88847-89-6 / 8-oxo-7-hydrodeoxyguanosine; EC 2.7.11.1 / Proto-Oncogene Proteins c-raf; EC 3.1.3.9 / Glucose-6-Phosphatase; G9481N71RO / Deoxyguanosine; GAN16C9B8O / Glutathione
  •  go-up   go-down


21. Dorsey M, Benghuzzi H, Tucci M, Cason Z: Growth and cell viability of estradiol and IP-6 treated Hep-2 laryngeal carcinoma cells. Biomed Sci Instrum; 2005;41:205-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth and cell viability of estradiol and IP-6 treated Hep-2 laryngeal carcinoma cells.
  • There was an increase in cell proliferation in Estradiol treated Hep-2 cells.
  • Cells treated with IP-6 showed no change in cell proliferation in the 24 or 48-hour groups, but there was a decrease in number with the 72-hour group, particularly with the 1mM dose.
  • The morphology showed small round to cuboidal, single cells with scant, dense, basophilic cytoplasm and hyperchromatic nuclei with smooth borders.
  • [MeSH-major] Cell Proliferation / drug effects. Cell Survival / drug effects. Estradiol / administration & dosage. Laryngeal Neoplasms / pathology. Laryngeal Neoplasms / physiopathology. Neoplasm Proteins / metabolism. Phytic Acid / administration & dosage
  • [MeSH-minor] Antineoplastic Agents / administration & dosage. Apoptosis / drug effects. Cell Line, Tumor. Cell Size / drug effects. Dose-Response Relationship, Drug. Drug Combinations. Humans. Treatment Outcome

  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15850106.001).
  • [ISSN] 0067-8856
  • [Journal-full-title] Biomedical sciences instrumentation
  • [ISO-abbreviation] Biomed Sci Instrum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Combinations; 0 / Neoplasm Proteins; 4TI98Z838E / Estradiol; 7IGF0S7R8I / Phytic Acid
  •  go-up   go-down






Advertisement